Evaluation of HER2 Mutations in Patient Tumors From E2598
- Correlate clinical response to trastuzumab (Herceptin®) with the presence of mutation
in the HER-2 kinase domain in tumor samples from patients with advanced non-small cell
lung cancer treated on protocol ECOG-2598.
- Correlate mutations with time to progression and survival of these patients.
OUTLINE: This is a multicenter study.
Tissue specimens are analyzed by polymerase chain reaction to assess mutations in the HER-2
gene. Laboratory/biomarker analysis data is correlated with clinical data from protocol
PROJECTED ACCRUAL: A total of 22-44 patients will be accrued for this study.
Correlation of HER-2 mutation with response, time to progression, and survival
David P. Carbone, MD, PhD
Vanderbilt-Ingram Cancer Center